Ligand Pharmaceuticals
| Company type | Public |
|---|---|
| Industry | Biopharmaceuticals |
| Founded | September 1987 |
| Founder | Brook Byers |
| Headquarters | Jupiter, Florida, U.S. |
Key people | Todd C. Davis (CEO) |
| Revenue | US$167.13 million (FY24) |
Number of employees | 68 (2024) |
| Website | ligand |
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company located in Jupiter, Florida. Founded in 1987 as Progenix Inc., the company went public in 1992. Initially focused on developing its own drugs, a period of turbulence in the early 2000s culminated in its CEO being ejected by the shareholders and provoked a change in focus to the acquisition of existing drugs and forming partnerships to develop them further.
The company has been the subject of multiple regulatory investigations, negative shorts-seller reports and class action lawsuits amid allegations of securities fraud.
In 2018 its CEO was listed among the top five highest paid CEOs in San Diego.